SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

May 26th 2015:Dr. Nicholas Kartsonis discusses the many contributions of Merck and ongoing research addressing CDI

Join us to hear from Merck's Dr. Nick Kartsonis, and the history in addressing infectious disease and antimicrobial resistance. Dr. Nick Kartsonis will also be discussing the future in the area of C. diff. and some of the company's current treatments, including DIFICID and their ongoing research addressing CDI.

Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Guest Image

Dr. Nicholas Kartsonis

Dr. Nicholas Kartsonis , Associate Vice President of Clinical Research for Infectious Diseases for Merck Research Laboratories (MRL) and Section Head within MRL for antibiotics, antibacterials and cytomegalovirus shares his time and discusses the past, present, and future contributions of Merck Research Laboratories. Dr. Kartsonis joined Merck Research Laboratories in February 2000 and has been actively involved in programs for new antibacterials, antifungals, anti-HIV, anti-CMV, and agents targeted against C. difficile infection. Most recently, he has led the efforts to ensure the integration of the Cubist Pharmaceuticals clinical research portfolio within Merck.
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 24/10/2017 10:00 24/10/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us to hear from Merck's Dr. Nick Kartsonis, and the history in addressing infectious disease and antimicrobial resistance. Dr. Nick Kartsonis will also be discussing the future in the area of C. diff. and some of the company's current treatments, including DIFICID and their ongoing research addressing CDI. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
Va Press pass